The Latest Breaking News from CMS

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Previously secret government audits reveal millions of dollars in overpayments to Medicare Advantage health plans

Panel of experts at Insider breakfast event states that existing oil and gas industry must be supported in move to renewables

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

The federal government says it will begin a targeted crackdown on nursing homes’ abuse of antipsychotic drugs and misdiagnoses of schizophrenia in patients

A new survey of the financial and professional services sector finds most firms are not enforcing minimum number of office days

The measures are aimed at stopping perpetrators from using child maintenance as a form of ongoing financial abuse and control

.

An Illinois Answers Project investigation found that the insurance giant fell short in providing basic care. Now, federal officials want answers from state agencies overseeing the program.

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

In 2018, responding to a wave of overdose deaths, Congress passed legislation requiring Medicare to pay for services at opioid treatment programs for the first time.